Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352412 | 0.89 | KMT2A (0.43) | KMT2AALDH1A1KDM4EMEN1MAPK1 | |
| SCHEMBL6348019 | 0.87 | KMT2A (0.42) | KMT2AALDH1A1KDM4EMEN1MAPK1 | |
| SCHEMBL6359355 | 0.82 | TP53 (0.42) | ALDH1A1MAPK1L3MBTL1TP53TSHR | |
| SCHEMBL6359360 | 0.81 | KMT2A (0.38) | KMT2AALDH1A1KDM4EMEN1L3MBTL1 | |
| SCHEMBL6350685 | 0.81 | KMT2A (0.38) | KMT2AALDH1A1KDM4EMEN1L3MBTL1 | |
| SCHEMBL6347885 | 0.76 | KMT2A (0.43) | KMT2AALDH1A1KDM4EMEN1MAPK1 | |
| SCHEMBL6350988 | 0.75 | MAPT (0.46) | KMT2AALDH1A1MEN1MAPK1GAA | |
| SCHEMBL6347795 | 0.72 | ALDH1A1 (0.43) | KMT2AALDH1A1MEN1MAPK1L3MBTL1 | |
| SCHEMBL6129112 | 0.72 | L3MBTL1 (0.59) | KMT2AALDH1A1KDM4EMEN1MAPK1 | |
| SCHEMBL6358312 | 0.71 | CTNNB1 (0.45) | KMT2AALDH1A1MEN1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960575-B2 | For use as inhibitors of chymase | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040097496-A1 | Novel thiazine derivatives | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-6713472-B1 | 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097496-A1 | Novel thiazine derivatives | CMA1, TPSD1, HRH4 | KMT2A 3612/4885ALDH1A1 420/4885KDM4E 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.